2. Search Result
Search Result
Results for "

Formal [3 1 1] Annulation

" in MedChemExpress (MCE) Product Catalog:

2969

Inhibitors & Agonists

2

Screening Libraries

15

Fluorescent Dyes

147

Biochemical Assay Reagents

149

Peptides

1

MCE Kits

28

Inhibitory Antibodies

193

Natural
Products

123

Recombinant Proteins

376

Isotope-Labeled Compounds

138

Antibodies

13

Click Chemistry

221

Oligonucleotides

4

GMP Molecules

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-18728
    STF-31
    15+ Cited Publications

    		 GLUT Autophagy Cancer
    STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC50 of 1 μM. STF-31 is also a NAMPT inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .
    STF-31
  • HY-117661
    SPHINX31
    10+ Cited Publications

    		 SRPK VEGFR Cardiovascular Disease Cancer
    SPHINX31 is a potent and selective SRPK1 inhibitor, with an IC50 of 5.9 nM. SPHINX31 inhibits phosphorylation of serine/arginine-rich splicing factor 1 (SRSF1). SPHINX31 also decreases the mRNA expression of pro-angiogenic VEGF-A165a isoform. SPHINX31 can be used to research neovascular eye disease .
    SPHINX31
  • HY-100433
    PACMA 31
    5 Publications Verification

    		 PDI Cancer
    PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues . PACMA 31 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    PACMA 31
  • HY-126077
    MTI-31
    1 Publications Verification

    LXI-15029

    		 mTOR Inflammation/Immunology Cancer
    MTI-31 (LXI-15029) is a potent, orally active and highly selective inhibitor of mTORC1 and mTORC2. MTI-31 is selective for mTOR (Kd: 0.20 nM) versus PIK3CA, PIK3CB and PIK3G with >5,000 fold selectivity in mTOR binding assays. MTI-31 shows an IC50 of 39 nM for mTOR in LANCE assay of mTOR substrate phosphorylation with 100 μM ATP. MTI-31 can be used for the research of breast cancer .
    MTI-31
  • HY-111655
    SKA-31
    4 Publications Verification

    		 Potassium Channel Cardiovascular Disease
    SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure .
    SKA-31
  • HY-156829I
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution)

    		Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors . The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature.
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (15% solution)
  • HY-133558
    VII-31
    2 Publications Verification

    		 E1/E2/E3 Enzyme Apoptosis Cancer
    VII-31 is a potent NEDDylation pathway activator to inhibit the tumor progression in vitro and in vivo. VII-31 induces apoptosis via intrinsic and extrinsic pathways .
    VII-31
  • HY-159805
    CDK2-IN-31

    		CDK Cancer
    CDK2-IN-31 is a CCNE1:CDK2 complex inhibitor with an IC50 of 0.13 μM. CDK2-IN-31 binds to a cryptic allosteric pocket at the CCNE1:CDK2 interface, inducing structural rearrangements of the CDK2 A-loop that disrupt the kinase's active conformation and interfere with substrate binding. CDK2-IN-31 inhibits phosphorylation of retinoblastoma protein 1 (RB1) in CCNE1-dependent ovarian cancer cells. CDK2-IN-31 impairs coenrichment of protein PRC1 with CCNE1-N112C:CDK2 complexes. CDK2-IN-31 can be used for the research of ovarian cancer .
    CDK2-IN-31
  • HY-156829J
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution)

    		Biochemical Assay Reagents Others
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) is a biodegradable thermosensitive hydrogel product that can undergo phase transition at a specific temperature. PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution) can be widely used in drug delivery systems, tissue engineering, wound dressings, and biosensors. The gelation temperature varies with the concentration; the higher the concentration, the lower the gelation temperature .
    PLGA-PEG-PLGA (hydrogel) (LA:GA 3:1) (20% solution)
  • HY-110155A
    (Rac)-LM11A-31 dihydrochloride

    		Drug Isomer Neurological Disease
    (Rac)-LM11A-31 dihydrochloride is an isomer of LM11A-31 dihydrochloride. LM11A-31 dihydrochloride, a non-peptide p75 NTR (neurotrophin receptor p75) modulator, is an orally active and potent proNGF (nerve growth factor) antagonist .
    (Rac)-LM11A-31 dihydrochloride
  • HY-W016825
    2-(Pyridin-2-yl)acetic acid hydrochloride

    		Drug Intermediate Others
    2-(Pyridin-2-yl)acetic acid hydrochloride is a heterocyclic aromatic carboxylic acid compound. 2-(Pyridin-2-yl)acetic acid hydrochloride can be used as an organic synthesis intermediate or a metal complex .
    2-(Pyridin-2-yl)acetic acid hydrochloride
  • HY-N7267
    31-Norlanostenol

    		Others Endocrinology
    31-Norlanostenol is a triterpenic compound isolated from the latex of Euphorbia officinarum. 31-Norlanostenol can act as efficient insect growth regulator on S. frugiperda and Tenebrio molitor .
    31-Norlanostenol
  • HY-141439
    TBE 31

    		Keap1-Nrf2 Quinone Reductase Glutathione S-transferase Apoptosis TNF Receptor Inflammation/Immunology Cancer
    TBE 31 is an orally active Keap1/Nrf2 pathway activator and NQO1 inducer with a Dm value of 1.1 nM for NQO1. TBE 31 binds to cysteine residues of Keap1, inhibits ubiquitination and degradation of Nrf2, thereby activating the expression of ARE-dependent genes. TBE 31 induces cytoprotective enzymes including NQO1 and GST isoforms, promotes Nrf2 accumulation, and upregulates Nrf2-regulated genes related to antioxidation and lipid metabolism. TBE 31 inhibits pro-inflammatory responses, formation of AFB1-DNA adducts, endoplasmic reticulum stress, cell apoptosis (apoptosis), hepatic fibrosis, oxidative stress, and the expression of ChREBP. TBE 31 reduces the number of tumors in a mouse model of ultraviolet-induced skin carcinogenesis. TBE 31 enhances nerve growth factor-induced neurite outgrowth. TBE 31 attenuates LPS-induced serum TNF-α levels and immobility time in mice. TBE 31 can be used in research related to liver cancer, skin cancer, inflammation-related depression, and non-alcoholic steatohepatitis .
    TBE 31
  • HY-P4160
    PDC31

    THG113.31; ILGHXDYK

    		 Prostaglandin Receptor Endocrinology
    PDC31 (THG113.31; ILGHXDYK) is an allosteric and non-competitive inhibitor of FP Prostaglandin Receptor. PDC31 is the D-amino acid-based oligopeptide, is used for smooth muscle contractile agent. PDC31 decreases the strength and duration of uterine contractions in vivo, which can be used for research of preterm labor and primary dysmenorrhea (PD). PDC31 also enhances Ca 2+-dependent large-conductance K +-channel in human myometrial cells .
    PDC31
  • HY-P2624A
    st-Ht31 ammonium

    		PAK Metabolic Disease
    st-Ht31 ammonium is a membrane-permeable peptide inhibitor of?protein kinase A (PKA) anchoring. st-Ht31 ammonium induces robust cholesterol/phospholipid efflux. st-Ht31 ammonium completely reverses foam cell formation and restores the metabolic health of macrophage .
    st-Ht31 ammonium
  • HY-125783S1
    1-Palmitoyl-sn-glycero-3-phosphocholine-d31

    16:0 Lyso PC-d31

    		 Isotope-Labeled Compounds Endogenous Metabolite Cardiovascular Disease Metabolic Disease Inflammation/Immunology
    1-Palmitoyl-sn-glycero-3-phosphocholine-d31 (16:0 Lyso PC-d31) is deuterium labeled 1-Palmitoyl-sn-glycero-3-phosphocholine (HY-125783). 1-Palmitoyl-sn-glycero-3-phosphocholine (16:0 Lyso PC) is an abundant lysophosphatidylcholine. 1-Palmitoyl-sn-glycero-3-phosphocholine exhibits proinflammatory activity. 1-Palmitoyl-sn-glycero-3-phosphocholine can be used in the study of atherosclerosis .
    1-Palmitoyl-sn-glycero-3-phosphocholine-d31
  • HY-P10380
    palm11-PrRP31

    		Neuropeptide FF Receptor Neurological Disease Metabolic Disease
    palm11-PrRP31 is a lipidized endogenous appetite inhibitory neuropeptide (PrRP) analogue. palm11-PrRP31 is GPR10 (EC50=39 pM) and NPFF-R2 effective dual agonists. palm11-PrRP31 is able to mimic the natural function of PrRP by binding to these receptors to reduce food intake. palm11-PrRP31 can be used as a potential anti-obesity agent and for the study of neuropeptide-receptor interaction .
    palm11-PrRP31
  • HY-N0830BS3
    Palmitic acid-d31 sodium

    		Isotope-Labeled Compounds Others
    Palmitic acid-d31 (sodium) is the deuterium labeled almitic acid .
    Palmitic acid-d31 sodium
  • HY-P2624
    st-Ht31

    		PAK Metabolic Disease
    st-Ht31 is a membrane-permeable peptide inhibitor of protein kinase A (PKA) anchoring. st-Ht31 induces robust cholesterol/phospholipid efflux. st-Ht31 completely reverses foam cell formation and restores the metabolic health of macrophage .
    st-Ht31
  • HY-W054225
    Aripiprazole impurity 31

    		Drug Intermediate Others
    Aripiprazole impurity 31 is an impurity of Aripiprazole.
    Aripiprazole impurity 31
  • HY-155050
    PRMT5-IN-31

    		Apoptosis Histone Methyltransferase Cancer
    PRMT5-IN-31 (Compound 3m) is a selective PRMT5 inhibitor (IC50: 0.31 μM). PRMT5-IN-31 up-regulates hnRNP E1 protein level. PRMT5-IN-31 occupies the substrate site of PRMT5 and forms essential interactions with amino acid residues. PRMT5-IN-31 has antiproliferative effects against A549 cells by inducing apoptosis and inhibiting cell migration. PRMT5-IN-31 has high metabolic stability on human liver microsomes (T1/2: 132.4 min) .
    PRMT5-IN-31
  • HY-179007
    TLR7 agonist 31

    		Toll-like Receptor (TLR) Cancer
    TLR7 agonist 31 (Compound 116) is a TLR7 agonist, with an EC50 of 31 nM. TLR7 agonist 31 can be used in the research of cancer .
    TLR7 agonist 31
  • HY-178156
    DHODH-IN-31

    		Dihydroorotate Dehydrogenase SARS-CoV Infection
    DHODH-IN-31 is a human dihydroorotate dehydrogenase (DHODH) inhibitor with an IC50 of 0.59 μM. DHODH-IN-31 exhibits antiviral activity. DHODH-IN-31 can be used for the research of infection, such as SARS-CoV-2 .
    DHODH-IN-31
  • HY-171951
    31hP

    		Liposome Others
    31hP is an asymmetric A 3 lipid. 31hP can facilitate in vivo luciferase expression. 31hP can be rapidly degraded in the presence of esterase owing to two biocleavable ester bonds. 31hP can be used in the synthesis of lipid nanoparticles (LNPs) .
    31hP
  • HY-144293
    HDAC-IN-31

    		Apoptosis HDAC Cancer
    HDAC-IN-31 is a potent, selective and orally active HDAC inhibitor with IC50s of 84.90, 168.0, 442.7, >10000 nM for HDAC1, HDAC2, HDAC3, HDAC8, respectively. HDAC-IN-31 induces apoptosis and cell cycle arrests at G2/M phase. HDAC-IN-31 shows good antitumor efficacy. HDAC-IN-31 has the potential for the research of diffuse large B-cell lymphoma .
    HDAC-IN-31
  • HY-146079
    Antifungal agent 31

    		Fungal Infection
    Antifungal agent 31 (compound 12) is a potent and orally active triazole antifungal agents with a pyrrolotriazinone scaffold. Antifungal agent 31 shows antifungal activity against Candida spp. and filamentous fungi. Antifungal agent 31 significantly reduced mortality rates and kidney fungal burden in two murine models of lethal systemic infections .
    Antifungal agent 31
  • HY-153546
    STING agonist-31

    		STING Cancer
    STING agonist-31 is a STING agonist, with EC50 values of 0.24 and 39.51 μM for h-STING and m-STING. STING agonist-31 has antitumor efficiency .
    STING agonist-31
  • HY-W272207
    AChE/BChE-IN-31

    		Cholinesterase (ChE) Drug Intermediate Neurological Disease Inflammation/Immunology
    AChE/BChE-IN-31 (Compound 3c) is a cholinesterase inhibitor. AChE/BChE-IN-31 exhibits certain inhibitory activity against hAChE and eqBChE. AChE/BChE-IN-31 also possesses antioxidant properties with an IC50 value of 105.04 μM against DPPH. AChE/BChE-IN-31 can be used in the research of diseases such as Alzheimer’s disease .
    AChE/BChE-IN-31
  • HY-125837
    MS31

    		Epigenetic Reader Domain Cancer
    MS31 is a potent, highly affinity and selective fragment-like methyllysine reader protein spindlin 1 (SPIN1) inhibitor. MS31 potently inhibits the interactions between SPIN1 and H3K4me3 (IC50=77 nM, AlphaLISA; 243 nM, FP). MS31 selectively binds Tudor domain II of SPIN1 (Kd=91 nM). MS31 potently inhibits binding of trimethyllysine-containing peptides to SPIN1. MS31 is not toxic to nontumorigenic cells .
    MS31
  • HY-156889
    Cav 3.1 blocker 1

    		Calcium Channel Neurological Disease
    Cav 3.1 blocker 1 (compound 12) is a T-type calcium channel blocker with an IC50value of 160 nM for Cav3.1. Cav 3.1 blocker 1 weakly inhibits Cav 3.2 (IC50 of 5000 nM), and shows no inhibition on Cav 3.3 and Cav 1.2 (IC50 of >10000 nM) .
    Cav 3.1 blocker 1
  • HY-P5574
    Aurein 3.1

    		Antibiotic Bacterial Infection
    Aurein 3.1 is an antibiotic antimicrobial peptide. Aurein 2.6 is active against Gram-positive bacterial (MIC: 80, 50, 50, 50, 50 μM for M. luteus, S. aureus, S. epidermis, S. mutans, B. subtilis) .
    Aurein 3.1
  • HY-111655R
    SKA-31 (Standard)

    		Potassium Channel Cardiovascular Disease
    SKA-31 (Standard) is the analytical standard of SKA-31. This product is intended for research and analytical applications. SKA-31 is a potent potassium channel activator with EC50s of 260 nM, 1.9 μM, 2.9 μM, and 2.9 μM for KCa3.1, KCa2.2, KCa2.1 and KCa2.3, respectively. SKA-31 potentiates endothelium-derived hyperpolarizing factor response and lowers blood pressure .
    SKA-31 (Standard)
  • HY-D2322
    SupraFlipper 31

    		Fluorescent Dye Others
    SupraFlipper 31 is a fluorescent probe. SupraFlipper 31 can be released in the membrane of interest (MOI) via chemical stimulation.
    SupraFlipper 31
  • HY-151996
    Tubulin inhibitor 31

    		Microtubule/Tubulin Cardiovascular Disease
    Tubulin inhibitor 31 is a potent tubulin inhibitor with an IC50 value of 4 μM. Tubulin inhibitor 31 shows anti-proliferative activity. Tubulin inhibitor 31 inhibits the HUVEC migration .
    Tubulin inhibitor 31
  • HY-170358
    Antileishmanial agent-31

    		Parasite Infection
    Antileishmanial agent-31 (Compound p1) is a pyrazole derivative. Antileishmanial agent-31 has anti-leishmania activity with an IC50 of 35.53 μg/mL. In addition, Antileishmanial agent-31 has high stability. Antileishmanial agent-31 can be used for anti-leishmaniasis research .
    Antileishmanial agent-31
  • HY-148782
    HBV-IN-31

    		HBV Infection
    HBV-IN-31 is a potent cccDNA (covalently closed circular DNA) inhibitor. HBV-IN-31 shows anti-HBV activity with an IC50 value of 0.13 µM for HBsAg. HBV-IN-31 inhibits cell growth .
    HBV-IN-31
  • HY-170321
    Apoptosis inducer 31

    		Apoptosis Cancer
    Apoptosis inducer 31 (compound 19) induces caspase-dependent apoptosis. Apoptosis inducer 31 plays an important role in cancer research .
    Apoptosis inducer 31
  • HY-139975
    Antitumor agent-31

    		Fluorescent Dye Cancer
    Antitumor agent-31 is a nanosized chelates of anchoring bisazo dye. Antitumor agent-31 can be used for an antioxidant and antitumor agent .
    Antitumor agent-31
  • HY-P5670
    Maximin 31

    		Bacterial Infection
    Maximin 31 is an antimicrobial peptide derived from the toad brain. Maximin 31 is active against Staphylococcus aureus and Escherichia coli, with MIC values of 37.5, 75 μg/mL, respectively .
    Maximin 31
  • HY-161846
    Tyrosinase-IN-31

    		Tyrosinase Neurological Disease
    Tyrosinase-IN-31 (compound 2-06) is a central-targeting tyrosinase inhibitor (tyrosinase: monophenolase IC50=70.44 μM, diphenolase IC50=1.89 μM). Tyrosinase-IN-31 can inhibit the tyrosinase and melanogenesis. Tyrosinase-IN-31 can penetrate the BBB and enter the central nervous system (CNS). Tyrosinase-IN-31 shows neuroprotective effects and Parkinsonism behavior improving function .
    Tyrosinase-IN-31
  • HY-158425
    Antimicrobial agent-31

    		Bacterial Infection
    Antimicrobial agent-31 (compound 4a) is a potent antimicrobial agent. Antimicrobial agent-31 inhibits Salmonella enterica serovar Typhimurium and E.coli with MIC values of 19.24, 11.31 µg/mL, respectively .
    Antimicrobial agent-31
  • HY-139052
    III-31-C

    		γ-secretase Neurological Disease
    III-31-C is a (hydroxyethyl)urea γ-secretase inhibitor. III-31-C inhibits Aऔ production with an IC50 of 10 nM in the cell-free γ-secretase assay and 200 nM in APP-transfected cells. III-31-C can be used in Alzheimer's disease research .
    III-31-C
  • HY-161926
    YGT-31

    		PPAR Metabolic Disease
    YGT-31 is a modulator for PPARγ with an IC50 of 1.72 μM, and a Ki of 0.62 μM. YGT-31 reduces blood glucose levels and improves insulin resistance in db/db mice type 2 diabetes models, through inhibition of CDK5-mediated PPARγ-Ser273 phosphorylation. YGT-31 exhibits anti-hepatic steatosis effect in mice non-alcoholic fatty liver disease (NAFLD) model .
    YGT-31
  • HY-163441
    BChE-IN-31

    		Cholinesterase (ChE) Neurological Disease
    BChE-IN-31 (Compound 14d) is a selective BChE inhibitor with an IC50 of 65 nM. BChE-IN-31 inhibits the self-induced aggregation of neurotoxic amyloid-β (Aβ) peptide .
    BChE-IN-31
  • HY-173493
    ALK-IN-31

    		Anaplastic lymphoma kinase (ALK) Apoptosis Akt mTOR Cancer
    ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor (IC50: 1135 nM). ALK-IN-31 exhibits excellent antiproliferative activity against lung cancer H2228 cells with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation in the G0/G1 phase by affecting mitochondrial function. ALK-IN-31 exerts its anti-tumor effect by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. ALK-IN-31 can be used in the study of non-small cell lung cancer (NSCLC) .
    ALK-IN-31
  • HY-146892S
    DPPC-d31-1

    129Y83-d31

    		 Isotope-Labeled Compounds Others
    1-Palmitoyl-2-palmitoyl-sn-glycero-3-phosphocholine-d31 is deuterium labeled 1-Palmitoyl-2-palmitoyl-sn-glycero-3-phosphocholine.
    DPPC-d31-1
  • HY-143302
    Anticancer agent 31

    		Apoptosis Cancer
    Anticancer agent 31 is a 1,3-diphenylurea quinoxaline derivative, and a anticancer agent. Anticancer agent 31 exhibits antitumor acitvity by arresting cell cycle at S phase and inducing apoptosis .
    Anticancer agent 31
  • HY-W074890S
    Palmitoylglycine-d31

    N-palmitoyl glycine-d31

    		 Calcium Channel NO Synthase Isotope-Labeled Compounds Others
    Palmitoylglycine-d31 is the deuterium labeled Palmitoylglycine .
    Palmitoylglycine-d31
  • HY-161328
    MAO-B-IN-31

    		α-synuclein Neurological Disease
    MAO-B-IN-31 (Compound 30) is an effective and selective inhibitor of monoamine oxidase B (monoamine oxidase B). The IC50 value is 41 nM. MAO-B-IN-31 also inhibits α-syn and tau aggregation. MAO-B-IN-31 has neuroprotective activity .
    MAO-B-IN-31
  • HY-151339
    Antitubercular agent-31

    		Bacterial Infection
    Antitubercular agent-31 (Compound 2) is an antitubercular agent with an MIC of 0.03 μM against M. tuberculosis H37Rv. Antitubercular agent-31 also inhibits DprE1 with an IC50 of 1.1 μM .
    Antitubercular agent-31

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: